Document is current
Any future updates will be listed below
-
Authors
Gopal, Aparna
Tam, Derek
Mey, Franziska https://orcid.org/0009-0000-3856-7123
Lin, Diana https://orcid.org/0000-0001-9645-3247
May, Christina https://orcid.org/0000-0003-2691-505X
Jiang, Jihong
Bridgers, Joshua
Caswell, Brett
O’Neill, Kieran
Vizeacoumar, Frederick S. https://orcid.org/0000-0002-4676-2911
MacAuley, Mackenzie
Haniak, Emilie
Craddock, Charles https://orcid.org/0000-0001-5041-6678
Vyas, Paresh https://orcid.org/0000-0003-3931-0914
Malcovati, Luca https://orcid.org/0000-0002-1460-1611
Buckstein, Rena
Moksa, Michelle
Hirst, Martin https://orcid.org/0000-0001-9136-9054
Vizeacoumar, Franco J. https://orcid.org/0000-0002-6452-5207
Medvedev, Nadia
Heuser, Michael
Stubbins, Ryan J.
Deng, Yu
Karsan, Aly https://orcid.org/0000-0001-6753-892X
-
Funding
Funding for this research was provided by:
Canadian Cancer Society Research Institute (705811)
Terry Fox Research Institute (1074)
V Foundation for Cancer Research (T2024-016)
Associazione Italiana per la Ricerca sul Cancro (31013)
- License Information
-
More Information
Article History
Received: 29 April 2025
Accepted: 6 May 2026
First Online: 22 May 2026
Competing interests
: Disclosures for R.J.S.: Honoraria or Advisory Board: AbbVie, Astellas, BMS, Kite/Gilead, Jazz Pharmaceuticals, Novartis. Disclosures for MH: Research funding to institution: Abbvie, Bayer Pharma AG, Jazz Pharmaceuticals, Glycostem, Karyopharm, PinotBio, Servier, Toray. Honoraria: Astellas, Daiichi Sankyo, Janssen, Miltenyi, Otsuka, Qiagen, Servier. Consultancy: Abbvie, AvenCell, Ascentage Pharma, Bristol Myers Squibb, Janssen, Jazz Pharmaceuticals, LabDelbert, Novartis, Pfizer, Servier. Disclosures for R.B.: BMS and Taibo contributed to funding for the registry from which some clinical samples were sourced. The other authors declare that they have no competing interests.
